Curis, Inc. Message Board

Search
Current Board
All Boards
Advanced Search
  • Subject Message Body
  • Topics Only Topics And Messages
  • biglabowski99 biglabowski99 • Jan 29, 2013 1:18 AM Flag

    907

    although much of the talk is surrounded around erivedge i believe the biggest and fastest way to double digits is cudc 907. go take a look and read up on infi and its rise from 6 to high 30's. 907 is now in patients so we might find out about toxicities fairly soon (hopefully nothing too bad) 907 could be very exciting and we own it so hopefully management keeps us informed. i feel that doing due diligence on 907 right now is more important thn E. read up on pi3k and hdac and blood cancers. seems like a legit approach. im still real curious about the lung trial with E.

    Sort:  Newest  |  Oldest  |  Most Replied Expand all replies
    • peterd96 peterd96 • Jan 29, 2013 10:30 AM Flag

      Big,

      Must be about growing up Aesop's fables or something similar, I have always a bird in hand kind of guy. Since you are trying to make the rest of us work harder, I actually e-mailed Genentech today about when we can expect update for OBCC trial (NCT01201915). One thing about this trial is they are bound to learn to administer the drug better which might actually increase applications. We'll see.

    • bentbasin bentbasin • Jan 29, 2013 7:28 AM Flag

      I'm also anxious for the operable and what that can do for revenues in a nearer term.

      Sentiment: Strong Buy

Back To Board
Previous topic Next topic
New Topic
 
CRIS
3.78-0.00(-0.03%)11:21 AMEDT